Electrolyte State in Patients With COVID-19

Initial case reports and cohort studies have described many clinical characteristics of patients with coronavirus disease 2019 (COVID-19), an emerging infectious disorder caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In early COVID-19 studies, some evidence has been provided that electrolyte disorders may also be present upon patients' presentation, including sodium, potassium, chloride and calcium abnormalities

the aim of the study is Identification of elements that affect COVID-19 pathology to improve survival and decrease mortality rate.

Study Overview

• Status: Completed
• Conditions: Electrolyte Imbalance
• Intervention / Treatment: Other: electrolytes

Detailed Description

SARS-CoV-2 invades human cells through binding angiotensin I converting enzyme 2 (ACE2) on the cell membrane. ACE2 is widely distributed in many types of human tissues, especially in the vital organs, such as heart, liver, kidney, and lungs. ACE2 is viewed as the principal counter-regulatory mechanism for the main axis of renin-angiotensin system (RAS) that is an essential player in the control of blood pressure and electrolyte balance. The final effect is to increase reabsorption of sodium and water, and thereafter increase blood pressure and excretion of potassium (K+). Besides, patients with COVID-19 often had gastrointestinal symptoms such as diarrhea and vomiting

Early studies proved that high percentage of COVID-19 patient were presented with electrolyte disorders, including sodium, potassium, chloride and calcium abnormalities. Such electrolyte disturbances have important implications not only for patient management but also for identifying potential pathophysiologic mechanisms underlying COVID-19 that could drive novel therapeutic opportunities

• Study Type: Observational
• Enrollment (Actual): 983

Contacts and Locations

Study Locations

• Egypt
  • Zagazig, Egypt, 055
    • Zagazig University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients ≥ 18 years old with diagnosis of COVID-19 infection who admitted to Isolation hospital of Zagazig University Hospitals during the period from 1 May 2020 to 1 August 2020.

Description

Inclusion Criteria:

• Patients ≥ 18 years old who were confirmed by the real-time PCR on the respiratory tract samples as positive of SARS-CoV-2.

Exclusion Criteria:

• Patients who had other causes of electrolyte disturbances (9):
• Chronic organ dysfunction (e.g., hepatic or renal dysfunction),
• Terminal cancer, immunodeficiency, and
• Patients with a history of long-term use of hormones & Diuretics were excluded.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
electrolytes disturbances in patients with COVID-19	Serum Electrolytes (Na, K, Ca, Cl, Ph, Mg) abnormality in COVID 19 patients laboratory results in the different stages of the disease	4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To asses the relation of the electrolyte disturbances with the severity of COVID-19 infection.	To find any correlation between the level of the electrolyte disturbances and the morbidity and mortality of the disease .	4 months

Collaborators and Investigators

• Sponsor: Zagazig University
• Investigators: Study Director: Tarek Hamdy, MD, lecturer of Chest diseases, Faculty of Medicine, Zagazig University; Principal Investigator: Hadeer El Shahaat, master degree, Assistant lecturer of Chest diseases, Faculty of Medicine, Zagazig University; Principal Investigator: Ahmed Abdulsaboor, MD, Clinical Pathology Department, Faculty of Medicine, Zagazig University

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2020
• Primary Completion (Actual): August 1, 2021
• Study Completion (Actual): October 30, 2021

Study Registration Dates

• First Submitted: September 1, 2020
• First Submitted That Met QC Criteria: September 3, 2020
• First Posted (Actual): September 7, 2020

Study Record Updates

• Last Update Posted (Actual): November 23, 2021
• Last Update Submitted That Met QC Criteria: November 20, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Keywords: Electrolytes; COVID-19
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: (ZU-IRB#: 6328-23-8-2020)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No